Quantitative Systems Pharmacology Modeling (QSPM) Case Study in Immuno-oncology
DATE: Tuesday, April 12, 2016 | TIME: 11am ET / 8am PT | DURATION: 1 Hour
Biotech and Pharma are increasingly using quantitative systems pharmacology modeling (QSPM) approaches to help answer complex, critical Go/No-go decisions in R&D.
Dr. John Burke will discuss the:
Value of QSP approaches
A QSP industry case study
The case study entails developing and interrogating a QSPM of PD-1 and TIM-3. The QSPM provided:
Biological insights by predicting why dosing regimens are quite similar for two therapeutics targeting PD-1 that have affinities that differ by several orders of magnitude
Best-in-class profile predictions for PD-1 and TIM-3 dual antagonists
This webinar is ideal for scientists in R&D who want to learn more about how to leverage QSPM to shorten timelines, lower cost, and increase the likelihood of developing best-in-class drugs.
John M. Burke, PhD — Co-Founder, President, and CEO, Applied BioMath
Prior to co-founding Applied BioMath, Dr. Burke was an Associate Director, Head of Systems Biology at Boehringer Ingelheim where he started, developed and managed the Systems Biology group, portfolio, and strategy. Prior to Boehringer Ingelheim, Dr. Burke was at Merrimack Pharmaceuticals, Co-Scientific Director of the Cell Decision Processes Center, Systems Biology Department, HMS, and was a Sr. Postdoctoral Fellow in Douglas A. Lauffenburger’s lab, Biological Engineering Department, MIT. Dr. Burke holds a PhD degree in Applied Mathematics from Arizona State University.